42 results about "Increase dose" patented technology

A system and method of diagnostic imaging is provided that includes determining a position of a subject in a scanning bay and tailoring x-ray attenuation such that the specific position of the subject is taken into consideration. The present invention automatically selects a proper attenuation filter configuration, corrects patient centering, and corrects noise prediction errors, thereby increasing dose efficiency and tube output.

A system and method of diagnostic imaging is provided that includes determining a position of a subject in a scanning bay and tailoring x-ray attenuation such that the specific position of the subject is taken into consideration. The present invention automatically selects a proper attenuation filter configuration, corrects patient centering, and corrects noise prediction errors, thereby increasing dose efficiency and tube output.

[Problem] As compared with the current oral sustained-release preparation containing tamsulosin hydrochloride which have been supplied to the medical setting at present, it is needed to provide a sustained-release pharmaceutical composition in which the efficacy is equivalent or even better, adverse events such as adverse reactions (e.g., postural hypotension) are reduced, dose can be increased and, if desired, ingestion of food is not limited in the dosage and it is also needed to provide a method for administration of tamsulosin hydrochloride in which the adverse reactions accompanied by therapy or prevention on the basis of an α1 receptor blocking action are reduced. [Means for Resolution] A sustained-release pharmaceutical composition, characterized in that, there are contained tamsulosin or a pharmaceutically acceptable salt thereof and a carrier for a sustained-release pharmaceutical composition and the ratio (Cmin / Cmax ratio) of the plasma tamsulosin concentration at 24 hours after the administration of the preparation per os (Cmin) to the maximum plasma tamsulosin concentration after the administration (Cmax) is about 0.4 or more.

The present invention is directed to determining, without repeated calculation by an operator, the volume of a non-solid composition remaining in the barrel of a syringe after discharge of a dose of the composition. The present invention provides a syringe barrel, and a plunger having a dose volume scale disposed along the longitudinal axis and orientated such that the numeric values increase in the direction from the proximal end of the plunger towards the discharge end. The dosage syringe also comprises an adjustable dose selector that may be moved to a volume mark of the scale corresponding to a desired dose to be delivered. The dose syringe barrel further comprises an indicator means that may be an opening in the barrel directly above the dose volume scale such that, when the plunger is in a fully retracted position, the window shows the volume of the full capacity of the syringe barrel and when the plunger is depressed, will show the remaining volume in the syringe.

A system and method of diagnostic imaging is provided that includes positioning a subject in an imaging device, performing at least one scout scan, and marking a user-defined region-of-interest. An attenuation characteristic of an attenuation filter is then automatically adjusted based on the user-defined region-of-interest. The present invention automatically selects a proper attenuation filter configuration, corrects patient centering, and corrects noise prediction errors, thereby increasing dose efficiency and tube output.

[Problem] As compared with the current oral sustained-release preparation containing tamsulosin hydrochloride which have been supplied to the medical setting, there is a problem to provide a sustained-release pharmaceutical composition in which efficacy is equivalent or even better, adverse events such as adverse reactions (e.g., postural hypotension) are reduced, dose can be increased and, if desired, ingestion of food is not limited. [Means for Resolution] A sustained-release pharmaceutical composition, characterized in that, there are contained tamsulosin or a pharmaceutically acceptable salt thereof and a carrier for a sustained-release pharmaceutical composition and, when dissolution test is carried out according to Japanese Pharmacopoeia Dissolution Test Method 2, the tamsulosin release after 7 hours from the start of the dissolution is about 20 to about 85%.

A system and method to manufacturing a device provide a substrate and perform at least one exposure step. Each exposure step projects a patterned beam of radiation, which was patterned using an individually controllable elements, onto a target portion of the substrate. The projected patterned beam includes a plurality of pixels. Each exposure step also: (a) ordinarily controls the elements, such that each pixel delivers a radiation dose no greater than a predetermined normal maximum dose to the target portion in the exposure step; and (b) exceptionally controls the elements, such that at least one selected pixel delivers an increased radiation dose, greater than the normal maximum dose. The increased dose may be delivered to compensate for the effect of a defective element at a known position in the array on a pixel adjacent a selected pixel. Alternatively, it may compensate for underexposure of the target portion at the location of a selected pixel resulting from exposure of that location to a pixel affected by a known defective element in another exposure step. The invention uses doses up to the predetermined normal maximum for normal printing, but reserves at least one increased dose for compensation purposes. Accordingly, even when a dead black pixel falls in the middle of a group of surrounding white pixels it can be compensated for by increasing the radiation dose delivered by one or more of those neighboring white pixels, above the normal fully white value.

The invention provides methods and compostions for treating lactose intolerance. In embodiments, the invention provides methods and composition for decreasing symptoms of lactose intolerance by administering to an individual suffering from lactose intolerance increasing doses of lactose using a protocol such that at the end of treatment the individual's symptoms of lactose intolerance are decrease and such that symptoms remain decreased after a period of time.

This is a new technique in IMRT and 3D conformal gamma radiation dose delivery using a linear accelerator with no flattening filter. The technique improves patient radiation therapy by reducing radiation scattered to surrounding normal tissue and reducing electron contamination. It increases dose rate to shorten treatment time. Linear accelerators have for decades come with a photon flattening filter to make the photon profile of planar fluence to make the dose distribution more uniform. These filters, however, resulted in fluence attenuation and contamination of the beam. Now in the age of techniques such as intensity modulated radiation therapy (IMRT) the function of the flattening filter becomes redundant. The flattening filter now merely reduces the efficiency of the beam by reducing the fluence and increasing scattered radiation. Our technique involves removal of the flattening filter for complex treatments. It uses inverse planning along with multi-leaf collimators to shape the dose distribution.

The present invention relates to the use of compounds of a cannabinoid nature for inhibiting viability with increasing doses of myeloma cell lines. Furthermore, said compounds have been shown not to affect CD34+ cells (normal hematopoietic progenitors) in terms of viability and proliferation. For this reason, the invention paves the way for the use of compounds of a cannabinoid nature as a promising therapy against multiple myeloma and related diseases.

This is a new technique in IMRT and 3D conformal gamma radiation dose delivery using a linear accelerator with no flattening filter. The technique improves patient radiation therapy by reducing radiation scattered to surrounding normal tissue and reducing electron contamination. It increases dose rate to shorten treatment time. Linear accelerators have for decades come with a photon flattening filter to make the photon profile of planar fluence to make the dose distribution more uniform. These filters, however, resulted in fluence attenuation and contamination of the beam. Now in the age of techniques such as intensity modulated radiation therapy (IMRT) the function of the flattening filter becomes redundant. The flattening filter now merely reduces the efficiency of the beam by reducing the fluence and increasing scattered radiation. Our technique involves removal of the flattening filter for complex treatments. It uses inverse planning along with multi-leaf collimators to shape the dose distribution.

A spray device including a casing and a spray bottle. A closing element is arranged in a nozzle. The closing element substantially fills the nozzle in order to minimize residual amounts of a drug in the nozzle. The overall purpose is to protect the spray device from contamination and evaporation. A method for manufacturing with as few parts as possible a spray device that by usually manual action causes the spray bottle to effect a pumping movement which triggers a spray dose through the nozzle. The device is intended to increase dose accuracy and facilitate the actual pumping.

The invention relates to a spray device which comprises a casing (1 ) and a spray bottle (2) and which has in its nozzle (5) a closing element which at the same time substantially fills the nozzle in order to minimise residual amounts of, preferably, a drug 5 in the nozzle, the overall purpose being to protect the spray device from contamination and evaporation. The invention further relates to a method for manufacturing with as few parts as possible a spray device which by usually manual action causes the spray bottle (2) to effect a pumping movement which triggers a spray dose through the nozzle (5). The device is intended to increase dose accuracy and facilitate the actual pumping.

The present invention relates to a method for substantially preventing a reduction in feed intake in an animal which occurs when said animal is administered an antibiotic, the method comprising administering to an animal in need of prevention of a reduction in feed intake, increasing doses of a composition comprising one or more antibiotics. The present invention also relates to a method for treating laminitis and fermentative acidosis in an animal in need of said treatment, the method comprising administering increasing doses of a composition comprising one or more antibiotics. The present invention further relates to a method for treating equine grass sickness and pulpy kidney in an animal in need of said treatment, the method comprising administering increasing doses of a composition comprising one or more antibiotics.

An NSAID formulation for encapsulation into a soft gel capsule with increased stability, concentration and bioavailability of the NSAID. The preferred NSAIDS are naproxen, ibprofen, indomethacin and diclofenac, which are provided in both an acidic and basic form in the fill formulation. The pH values of fill formulations may be adjusted without additional process steps. A process for increasing the achievable concentration of an NASAID pharmaceutical ingredient in a fill composition for dosage units is also provided. The highly concentrated NASAID formulation permits a reduction in the fill volume or dosage unit size or an increase in concentration of the NSAID in each dosage it.

A method is provided for reducing the occurrence of fever, headache, nausea and / or vomiting associated with administration of a therapeutic compound to a mammal in need therof, comprising administering to the mammal a first conditioning dose of a non-target cell depleting compound which binds to a cell surface receptor on a target mammalian cell; and administering a second therapeutic dose of the compound, wherein the second dose is higher than the first dose.

The invention relates to the field of proteins, in particular to application of recombinant human calcineurin B subunit, and mainly provides application of rhCNB to preparation of a medicine for killing and / or inhibiting a liver cancer cell Bel-7402. After continuous medication for 6 times, medication groups of rhCNB for injection with doses of 10 mg / kg, 20 mg / kg and 40 mg / kg all have a relatively good inhibiting effect on the growth of human liver cancer cell Bel-7402 solid tumors. Subsequent testing results show that the effects of high-dose, middle-dose and increasing-dose medication groups are superior to that of a low-dose medication group, and the treating effect of rhCNB for injection is equivalent to those of recombinant human interleukin-2 for injection and hydroxycamptothecine for injection in a solvent control group. The results of d7 testing after final medication show that the high-dose group has the optimum controlling effect (p is smaller than 0.01) on tumor cell proliferation, which is superior to those of other dose groups and a positive control group, and equivalent to those of a hydroxycamptothecine medication group and the increasing-dose group (p is smaller than 0.05).

Sublingual immunotherapy (SLIT) with reduced oral itchiness is disclosed. The improved sublingual immunotherapy combines a monotonically increasing dose of allergen, along with a constant dose of mast cell stabilizer, thereby substantially avoiding the oral itchiness and other uncomfortable adverse reactions typically experienced with SLIT, which can improve patient compliance. An antihistamine and / or a leukotriene inhibitor can also be added along with the mast cell stabilizer. Multi-layer and / or coated tablets, and flexible paired ampoules with special features to advantageously time the dose of the allergen relative to the dose of the mast cell stabilizer, have been provided to effectively administer the improved sublingual immunotherapy in a highly convenient manner. Methods, preparations, and apparatuses for administration of SLIT, apparatus for sequentially dispensing, methods for producing a sequence of allergen doses with reduced adverse reactions, methods for producing a stock solution for dilution, and methods for producing cooperative pre-filled vials are also disclosed.

Carbamazepine, in extended release form, is useful in the treatment of patients suffering from bipolar disorder. In order to minimize the time it takes to reach efficacy, carbamazepine, in extended release form, can be administered to the patient at an initial daily dose which is then increased in daily increments until clinical efficacy is achieved.

Photon-based radiosurgery is widely used for treating local and regional tumors. The key to improving the quality of radiosurgery is to increase the dose falloff rate from high dose regions inside the tumor to low dose regions of nearby healthy tissues and structures. Dynamic photon painting (DPP) further increases dose falloff rate by treating a target by moving a beam source along a dynamic trajectory, where the speed, direction and even dose rate of the beam source change constantly during irradiation. DPP creates dose gradient that rivals proton Bragg Peak and outperforms Gamma Knife® radiosurgery.

Certain R5 virus tropic HIV-1 subjects with viral load effectively conventionally controlled using HAART, i.e., subject having less than 50 viral copies / mL (<50 cp / mL), may be substantially more susceptible than others to effective monotherapy treatment using anti-CCR5 agents, e.g, PRO 140 mAbs. Certain HIV-1 subjects using PRO 140 monotherapy treatment may experience prolonged or unlimited time periods with actual undetectable viral loads, extremely low viral load counts ≤1 cp / mL, very low, or low levels, or at conventionally undetectable levels, during monotherapy. Increasing dose amounts of anti-CCR5 agents, e.g., PRO 140, from 350 mg to 525 mg or 700 mg, may beneficially suppress a subject's viral load count before, during, and / or maintain effective prolonged monotherapy and may shorten the period of time necessary to determine if a subject will respond positively to PRO 140 monotherapy to less than eight (8) weeks. This invention includes protocols, methods, and kits.

A method for testing diseased skin for treatment of the diseased skin, comprising the steps of administering a plurality of increasing doses of phototherapy directly to regions of an area of diseased skin and analyzing the area of the diseased skin to assess the doses at which burning and blistering of the diseased skin occurs, determining a maximum dose of phototherapy that can be administered to the diseased skin based on the assessment of the doses at which the burning and the blistering of the diseased skin occurs, and treating the diseased skin.